Johnson & Johnson fined nearly $30 million for impeding generic drugs to market
Posted On: Dec. 21, 2017 4:52 AM CSTFrance's competition regulator has fined U.S. healthcare firm Johnson & Johnson Inc. $29.6 million after it found that the company had deliberately slowed market access to generic copies of its painkiller Durogesic, CNBC reported citing Reuters. The regulator said that Johnson & Johnson's unit Janssen-Cilag S.A.S. had "repeatedly intervened" to block the approval processes of Durogesic's generic copies and disparaged them when in contact with healthcare professionals. The case was filed by German pharmaceutical firm Ratiopharm GmbH.